Marchetti, A <br/><br/>
Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin.  [electronic resource] 

 -  Clinical therapeutics  Apr 2000 
 - 422-38 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0149-2918 
<br/><br/><label>Standard No.: </label>10.1016/s0149-2918(00)89011-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>BCG Vaccine<br/>Carcinoma in Situ--drug therapy<br/>Costs and Cost Analysis<br/>Cystectomy--economics<br/>Doxorubicin--administration & dosage<br/>Humans<br/>Injections<br/>Models, Economic<br/>Urinary Bladder<br/>Urinary Bladder Neoplasms--drug therapy